Dr. Burchard is a Latino physician-scientist. He initiated and now directs the largest study of asthma in minority children in the U.S. and is currently the lead PI involving a birth cohort of minority children in Puerto Rico. Dr. Burchard is the Director of the UCSF Asthma Collaboratory, a large interdisciplinary research program focusing on minority children and gene-environment interactions for asthma. Dr. Burchard’s team was the first to leverage genetic ancestry to identify novel genetic and environmental risk factors for lung disease and poor drug response among minority children with asthma. Dr. Burchard earned his MD from Stanford University School of Medicine, completed residency at the Brigham and Women's Hospital, MA and a fellowship at the University of California, San Francisco. Dr. Burchard has formal training and expertise in internal medicine, pulmonary and critical care medicine, epidemiology, molecular genetics, genetic and clinical research.
Making Precision Medicine Socially Precise
How minority children with severe asthma do not qualify for modern asthma biologic drugs because of racial variation in targeted biomarkers
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.